<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992312</url>
  </required_header>
  <id_info>
    <org_study_id>17449</org_study_id>
    <secondary_id>I8R-MC-IGBO</secondary_id>
    <nct_id>NCT04992312</nct_id>
  </id_info>
  <brief_title>A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes</brief_title>
  <acronym>RescuiNGkids</acronym>
  <official_title>An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to &lt;4 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of a study drug&#xD;
      called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1&#xD;
      to less than 4 years. Blood tests will be performed to check how much nasal glucagon gets&#xD;
      into the bloodstream. Blood sugar will also be measured to understand the effect of the drug&#xD;
      on blood sugar levels. The study consists of a screening period up to 35 days before dosing,&#xD;
      1 day when a dose of nasal glucagon will be given and then 2 telephone follow up calls; first&#xD;
      follow-up call on the day after the nasal glucagon was given and second call about one week&#xD;
      after nasal glucagon was given. The study will last up to 9 days, not including the screening&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 6, 2021</start_date>
  <completion_date type="Anticipated">December 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 9</time_frame>
    <description>A summary of SAEs, TEAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Change From Baseline in Maximum Observed Blood Glucose (BGmax) of Nasal Glucagon</measure>
    <time_frame>Predose through Day 1</time_frame>
    <description>PD: Change From Baseline in BGmax of Nasal Glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Absolute BGmax of Nasal Glucagon</measure>
    <time_frame>Predose through Day 1</time_frame>
    <description>PD: Absolute BGmax of Nasal Glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Time of Maximum Observed Blood Glucose (TBGmax) of Nasal Glucagon</measure>
    <time_frame>Predose through Day 1</time_frame>
    <description>PD: TBGmax of Nasal Glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Area Under the Concentration Versus Time Curve (AUC) of Plasma Glucose</measure>
    <time_frame>Predose through Day 1</time_frame>
    <description>PD: AUC of Plasma Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUC of Nasal Glucagon</measure>
    <time_frame>Predose through Day 1</time_frame>
    <description>PK: AUC of Nasal Glucagon</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Glucagon Nasal Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of glucagon nasal powder administered intranasally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon Nasal Powder [Baqsimi]</intervention_name>
    <description>Administered intranasally</description>
    <arm_group_label>Glucagon Nasal Powder</arm_group_label>
    <other_name>LY900018</other_name>
    <other_name>Baqsimi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a Type 1 Diabetes diagnosis for at least 6 months&#xD;
&#xD;
          -  Have been receiving insulin therapy via multiple daily injections or using an insulin&#xD;
             pump and have been stable for at least 3 months prior to screening&#xD;
&#xD;
          -  Have a HbA1c level of â‰¤ 9.0% at screening&#xD;
&#xD;
          -  Have sufficient venous access for collection of blood samples&#xD;
&#xD;
          -  Have good general health, apart from their Type 1 diabetes, with no prior history of&#xD;
             choanal atresia, nasal/pharyngeal blockage or nasal anomaly&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a presence or history of glucagon hypersensitivity&#xD;
&#xD;
          -  Have a history of pheochromocytoma&#xD;
&#xD;
          -  Have a history of epilepsy or seizure disorder&#xD;
&#xD;
          -  Have 1 or more congenital anomalies to the anatomy of the nose, or require changes to&#xD;
             the anatomy of the nose&#xD;
&#xD;
          -  Are using closed-loop insulin therapy, unless such a device is set to 'open&#xD;
             loop/manual' mode on the day of the dosing visit&#xD;
&#xD;
          -  Have an episode of severe hypoglycemia or have had glucagon administered , during the&#xD;
             3 months prior to the screening visit and no severe hypoglycemia between the screening&#xD;
             and dosing visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>323-361-7040</phone>
    </contact>
    <investigator>
      <last_name>Roshanak Monzavi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Childrens Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>904-697-3910</phone>
    </contact>
    <investigator>
      <last_name>Larry A Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>208-381-7340</phone>
    </contact>
    <investigator>
      <last_name>Daniel Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>317-944-3889</phone>
    </contact>
    <investigator>
      <last_name>Linda DiMeglio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children Mercy Pediatric Clinical Research Unit</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>816-983-6982</phone>
    </contact>
    <investigator>
      <last_name>Mark A Clements</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UBMD Pediatrics</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>716-323-0170</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Bethin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>513-636-4744</phone>
    </contact>
    <investigator>
      <last_name>Nicole Sheanon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>267-426-7037</phone>
    </contact>
    <investigator>
      <last_name>Steven M. Willi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/3M5oZzkbDqRlSiqf7KNpeL</url>
    <description>A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes (RescuiNGkids)</description>
  </link>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Hypoglycemia</keyword>
  <keyword>Nasal Powder</keyword>
  <keyword>Hypoglycemia Rescue Therapy</keyword>
  <keyword>Ready to use Glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

